Trimeris Overview

  • Founded
  • 1993

Founded
  • Status
  • Acquired/​Merged

  • Employees
  • 172

Employees
  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $285M

Trimeris General Information

Description

Trimeris was a developer of commercial applications of antiviral drug treatments that utilized a class of fusion inhibitors. The company developed novel anti-human immunodeficiency virus therapeutics. It was acquired by Synageva on November 3, 2011.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Medical Supplies
Primary Office
  • 2530 Meridian Parkway
  • Second Floor
  • Durham, NC 27713
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Trimeris Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 03-Nov-2011 $285M 00000 00000 Completed Generating Revenue
6. PIPE 00000 Completed
5. PIPE 04-Feb-2002 000.00 00000 Completed Generating Revenue
4. IPO 07-Oct-1997 0000 000.00 00000 Completed Generating Revenue
3. Later Stage VC (Series C) 00.000 000.00 Completed
2. Early Stage VC (Series B) $26.1M $29.1M Completed
1. Early Stage VC (Series A) $3M $3M Completed
To view Trimeris’s complete valuation and funding history, request access »

Trimeris Patents

Trimeris Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-2700354-A1 Novel methods of synthesis for therapeutic antiviral peptides Inactive 25-Sep-2007 0000000000
EP-2201028-A2 Novel methods of synthesis for therapeutic antiviral peptides Inactive 25-Sep-2007 0000000000
EP-2139526-A4 Novel formulations for delivery of antiviral peptide therapeutics Inactive 03-Apr-2007 0000000000
EP-2139526-A1 Novel formulations for delivery of antiviral peptide therapeutics Inactive 03-Apr-2007 0000000000
CA-2682848-A1 Novel formulations for delivery of antiviral peptide therapeutics Inactive 03-Apr-2007 A61K38/162
To view Trimeris’s complete patent history, request access »

Trimeris Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Trimeris Former Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Domain Associates Venture Capital Minority 000 0000 000000 0
Four Partners Corporation Minority 000 0000 000000 0
Lawrence & Co. Corporation Minority 000 0000 000000 0
Pacific Horizon Ventures Venture Capital Minority 000 0000 000000 0
Rothschild Bioscience Unit Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »

Trimeris Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 0000 03-Nov-2011 0000000 00 00000 Biotechnology
To view Trimeris’s complete acquisitions history, request access »

Trimeris Exits (1)

Company Name Exit Date Exit Type Exit Size Status Buyers
00000000 000000000 03-Nov-2011 0000000 000000 00000 Completed
  • 00000000
To view Trimeris’s complete exits history, request access »